Sample Report

Digital & Computational Pathology Market Report – Second Edition: 2024 - 2029

The second edition of this report provides an overview of the digital pathology market from 2024 to 2029. The digital pathology market, as defined in this report, is comprised of revenue from instruments and software sold to clinical, academic, biopharma, and CRO customers, along with service revenues generated by CROs and reference labs.

See more details below.

Complete this form to receive a copy of the sample report.

Customer:

AMC Clinical
Community Hospital
Large Biopharma
Small Biopharma
CRO / Reference Labs

Products & Services:

Scanners / Image acquisition
Image Management Software
Image Analysis / AI Algorithms
Custom Image Analysis Development Services
Other Services

Histological Method:

IHC
H&E
Immunofluorescence
In-situ Hybridization
Spatial

Application:

Basic & Translational Research
Clinical Research & Trials
Routine Clinical
Training & Slide Archiving

Therapeutic Area:

Oncology
Liver Disease
Infectious Disease
Neurology
Other

Technologies and Revenues Included:

Digital pathology / image analysis in which automated image analysis, algorithms, or pathologist-supported software is used to perform image analysis of any sort from an image of a scanned slide
3rd Party Image Analysis performed by a standalone image analysis company or spatial image analysis performed by a standalone image analysis company
Technology classes which are designed to profile and analyze biomarkers including IF, IHC, H&E, digital-spatial profiling, and ISH
Instrument and software revenues associated with the purchase of digital pathology platforms (e.g., slide scanners) or software used to run the assays and analyze the data, and service revenues associated with the processing or analysis of slides (e.g., by CROs / Reference Labs) or CDx development
Global sales of products and services to academic, clinical, biotech / pharmaceutical companies, and CRO customers

Technologies and Revenues Excluded:

Instrumentation, assays, and reagents upstream of slide digitization (e.g., autostainers, dyes, and antibodies), including spatial biology instrument and reagent revenues
Spend downstream of image analysis (e.g., data storage and compute is assessed qualitatively but not included in the model)
Spatial analysis conducted on-platform or offered by instrument manufacturers (e.g., analytics tools provided by Nanostring, 10x)
Digital cytology platforms and technologies
Service revenues passed to CROs / reference labs for slide staining
Service revenue related to CDx development

Updated Content:

Incorporated the latest trends in the Digital & Computational Pathology market, based on interviews (N = 35) with experts, a clinically-focused survey (N =100), a biopharma-focused survey (N = 40), and extensive secondary research
Updated our database of Digital & Computational Pathology companies and their offerings, highlighting key recent activity and product updates
Updated market sizing, segmentation, and forecast based on primary research findings and publicly-available information
Evaluated emerging, high-growth applications in depth, elucidating both quantitative and qualitative market drivers, moderators, and trends, including a new deep-dive on the computational pathology market landscape
Included primary vendor feedback on perceived strengths and weaknesses, as well as stakeholder familiarity and satisfaction scores as part of the Global Report License